Jan 31 (Reuters) - Eli Lilly And Co:
* LILLY REPORTS STRONG FOURTH-QUARTER AND FULL-YEAR 2017 REVENUE GROWTH, INCREASES 2018 EPS GUIDANCE
* Q4 NON-GAAP EARNINGS PER SHARE $1.14
* Q4 EARNINGS PER SHARE VIEW $1.07 — THOMSON REUTERS I/B/E/S
* SEES FY 2018 EARNINGS PER SHARE $4.39 TO $4.49 INCLUDING ITEMS
* FOR Q4 2017, ALIMTA GENERATED WORLDWIDE REVENUE OF $525.2 MILLION, WHICH DECREASED 3 PERCENT
* ELI LILLY - RECORDED ESTIMATED CHARGE OF $1.9 BILLION IN QUARTER ASSOCIATED WITH U.S. TAX REFORM LEGISLATION, CHARGES ASSOCIATED WITH REDUCING COST STRUCTURE
* QTRLY JARDIANCE SALES $143.2 MILLION VERSUS $76.1 MILLION
* COMPANY STILL ANTICIPATES 2018 REVENUE BETWEEN $23.0 BILLION AND $23.5 BILLION
* SAYS QTRLY CYMBALTA SALES $192.8 MILLION VERSUS $181.8 MILLION
* FY2018 EARNINGS PER SHARE VIEW $4.68, REVENUE VIEW $23.21 BILLION — THOMSON REUTERS I/B/E/S
* ELI LILLY - 2018 REV GROWTH EXPECTED TO BE DRIVEN BY NEW PRODUCTS INCLUDING TRULICITY, TALTZ, BASAGLAR, JARDIANCE, VERZENIO, CYRAMZA, OLUMIANT, LARTRUVO
* ELI LILLY AND CO - DURING 2017, CO RECORDED INCOME TAX EXPENSE OF $2.402 BLN, WHICH INCLUDED AN ESTIMATED TAX CHARGE OF $1.914 BLN Source text for Eikon: Further company coverage: